Pharmaceutical stocks are making a comeback as valuations remain attractive and companies successfully address patent cliff concerns, according to UBS global head of biotech research Michael Yee. In ...

Eli Lilly said on Monday it would buy privately held cancer drug developer Ajax Therapeutics for up to $2.3 billion in cash, as the U.S. drugmaker looks to expand its oncology pipeline. Lilly has been ...

Add Yahoo as a preferred source to see more of our stories on Google. April 19 (Reuters) - U.S. drugmaker Eli Lilly (LLY) is in advanced talks to acquire biotech firm Kelonia ‌Therapeutics for more ...

Eli Lilly said it has agreed to acquire biotech company Kelonia Therapeutics. Lilly will pay $3.25 billion upfront and up to $7 billion in total, the company said. Kelonia is developing technology to ...

Just a few months after ripping up the central nervous system-focused portion of its RIPK1 deal with Rigel Pharmaceuticals, Eli Lilly has now thrown out the rest of the pact too. Lilly notified Rigel ...

Pharmaceutical powerhouse Eli Lilly & Co. will buy Boston gene therapy maker Kelonia Therapeutics for at least $3.25 billion, the companies announced Monday. The acquisition will grant ...

Eli Lilly (LLY) is in advanced negotiations to acquire Kelonia Therapeutics in a transaction valued at more than $2 billion, The Wall Street Journal reported Sunday, citing people familiar with the ...

Eli Lilly & Co.’s new weight-loss pill Foundayo has gotten off to a sluggish start, according to new prescription data, an early sign of the challenge the drugmaker will have as it tries to catch up ...

Following a quiet stretch, the legal back-and-forth over migraine meds from Teva and Eli Lilly has resurfaced, with Teva gaining favor on appeal after a 2023 reversal of its prior patent win. The ...

Investors often mistake share price for valuation. While Eli Lilly's stock price looks expensive on the surface, the company's underlying valuation metrics are quite modest. Eli Lilly stock might ...

Eli Lilly is spending some of its GLP-1 money to buy up CAR-T gene therapy researchers. UBS analyst Michael Yee thinks that's smart strategy. So what does this Wall Street analyst like about Lilly?

Kelonia specializes in 'in vivo' CAR-T therapies for cancer Deal includes $3.25 bln upfront and milestone payments Deal price reflects strong data and sector competition - analyst April 20 (Reuters) - ...